| A controlled trial of erenumab for episodic migraine PJ Goadsby, U Reuter, Y Hallström, G Broessner, JH Bonner, F Zhang, ... New England Journal of Medicine 377 (22), 2123-2132, 2017 | 910 | 2017 |
| ARISE: a phase 3 randomized trial of erenumab for episodic migraine DW Dodick, M Ashina, JL Brandes, D Kudrow, M Lanteri-Minet, V Osipova, ... Cephalalgia 38 (6), 1026-1037, 2018 | 560 | 2018 |
| The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences H Picard, I Amado, S Mouchet-Mages, JP Olié, MO Krebs Schizophrenia bulletin 34 (1), 155-172, 2008 | 303 | 2008 |
| Early onset of efficacy with erenumab in patients with episodic and chronic migraine T Schwedt, U Reuter, S Tepper, M Ashina, D Kudrow, G Broessner, ... The Journal of Headache and Pain 19, 1-8, 2018 | 100 | 2018 |
| Vascular safety of erenumab for migraine prevention D Kudrow, J Pascual, PK Winner, DW Dodick, SJ Tepper, U Reuter, ... Neurology 94 (5), e497-e510, 2020 | 91 | 2020 |
| Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab DC Buse, RB Lipton, Y Hallström, U Reuter, SJ Tepper, F Zhang, S Sapra, ... Cephalalgia 38 (10), 1622-1631, 2018 | 79 | 2018 |
| A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine … M Ashina, D Doležil, JH Bonner, L Zhou, J Klatt, H Picard, DD Mikol Cephalalgia 41 (1), 33-44, 2021 | 69 | 2021 |
| One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study PJ Goadsby, U Reuter, Y Hallström, G Broessner, JH Bonner, F Zhang, ... Neurology 95 (5), e469-e479, 2020 | 62 | 2020 |
| Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo … PJ Goadsby, K Paemeleire, G Broessner, J Brandes, J Klatt, F Zhang, ... Cephalalgia 39 (7), 817-826, 2019 | 62 | 2019 |
| Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four … M Ashina, D Kudrow, U Reuter, D Dolezil, S Silberstein, SJ Tepper, F Xue, ... Cephalalgia 39 (14), 1798-1808, 2019 | 60 | 2019 |
| Efficacy and safety of erenumab in women with a history of menstrual migraine JM Pavlovic, K Paemeleire, H Göbel, J Bonner, A Rapoport, R Kagan, ... The journal of headache and pain 21, 1-9, 2020 | 42 | 2020 |
| Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study I Romera, V Perez, JM Menchón, A Schacht, R Papen, D Neuhauser, ... Journal of affective disorders 143 (1-3), 47-55, 2012 | 33 | 2012 |
| Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trials A Schacht, P Gorwood, P Boyce, A Schaffer, H Picard Journal of psychiatric research 53, 54-61, 2014 | 23 | 2014 |
| Reading impairment in schizophrenia: dysconnectivity within the visual system F Vinckier, L Cohen, C Oppenheim, A Salvador, H Picard, I Amado, ... Neuropsychologia 53, 187-196, 2014 | 18 | 2014 |
| Correlates between neurological soft signs and saccadic parameters in schizophrenia HJ Picard, I Amado, MC Bourdel, S Landgraf, JP Olié, MO Krebs Progress in Neuro-Psychopharmacology and Biological Psychiatry 33 (4), 676-681, 2009 | 18 | 2009 |
| Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign scores H Picard, A Le Seac'h, I Amado, R Gaillard, MO Krebs, C Beauvillain Psychiatry research 199 (1), 12-18, 2012 | 17 | 2012 |
| The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving≥ 50%,≥ 75%, and 100% response G Broessner, U Reuter, JH Bonner, DW Dodick, Y Hallström, H Picard, ... Headache: The Journal of Head and Face Pain 60 (9), 2026-2040, 2020 | 13 | 2020 |
| Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure (s) PJ Goadsby, K Paemeleire, G Broessner, J Brandes, J Klatt, F Zhang, ... 18th International Headache congress (IHC) of the International Headache …, 2017 | 13 | 2017 |
| Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials SJ Tepper, M Ashina, U Reuter, Y Hallström, G Broessner, JH Bonner, ... The Journal of Headache and Pain 22, 1-14, 2021 | 12 | 2021 |
| A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial D Dodick, M Ashina, D Kudrow, M Lanteri-Minet, V Osipova, K Palmer, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (5), e1-e1, 2017 | 11 | 2017 |
